Clinical trials: Synucleinopathy
Parkinson Disease
Feasibility and Effect of a Strategy-Based Cognitive Intervention for Parkinson Disease
Parkinson disease (PD) affects over 1 million Americans and causes considerable personal and socioeconomic costs (>$34 billion/year in the US) that are expected to rise as the population ages.
- Trial name
- NCT04048122
- Testing
- MultiContext for PD Strategy Training, Standard of Care
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Washington University School of Medicine
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Parkinson Disease
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia…
- Trial name
- NCT04387773
- Testing
- GOCOVRI
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oregon Health and Science University
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Parkinson Disease
Low Frequency Subthalamic Nucleus Deep Brain Stimulation to Improve Verbal Fluency
Rationale: Parkinson's disease patients with deep brain stimulation electrodes represent a unique opportunity to study the influence of basal ganglia on neurocognitive function.
- Trial name
- NCT04383665
- Testing
- STN DBS 10Hz, STN DBS 130Hz, STN DBS off
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Southern California
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical…
- Trial name
- TOLEDO (NCT02006121)
- Testing
- Apomorphine hydrochloride
- Where
- 20 sites in Austria, Denmark and 5 more
- Volunteers
- 107 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Parkinson's Disease
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease…
- Trial name
- PASADENA (NCT03100149)
- Testing
- RO7046015
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Study of Parkinson's Early Stage With Deferiprone
The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. Participants will be randomized to receive one of four different dosages of deferiprone or placebo…
- Trial name
- SKY (NCT02728843)
- Testing
- Deferiprone
- Where
- 20 sites in Canada, France and 2 more
- Volunteers
- 140 people
- Sponsor
- ApoPharma
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease
- Trial name
- BUTTER (NCT05446168)
- Testing
- tributyrin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nicolaas Bohnen, MD, PhD
Parkinson Disease
The Benchmark Clinic: An Interdisciplinary Comprehensive Care Model for People With Parkinson Disease
The purpose of this study is to determine if an interdisciplinary clinic can help people with Parkinson's disease care for themselves, improve their ability to follow recommended treatments, and have fewer problems like falls or…
- Trial name
- NCT04555720
- Testing
- Interdisciplinary Visit
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Duke University
Multiple System Atrophy
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Fifty patients with early stage Multiple System Atrophy (MSA) will be recruited and randomised to receive Exenatide injections, or to act as controls in this open label trial.
- Trial name
- MSA (NCT04431713)
- Testing
- Exenatide Pen Injector [Bydureon]
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Parkinson's Disease, Deep Brain Stimulation
Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation
Does dual hemispheric stimulation of the subthalamic nucleus (STN) and fornix/hypothalamus potentially improve cognitive function in patients with Parkinsons disease.
- Trial name
- NCT01563341
- Testing
- Deep brain stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Parkinson's Disease
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
- Trial name
- NCT02337738
- Testing
- TVP-1012 1mg, TVP-1012 0.5mg
- Where
- 57 sites in Japan
- Volunteers
- 404 people
- Sponsor
- Takeda
Parkinson Disease
Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.
- Trial name
- CLOVER (NCT03037398)
- Testing
- Vercise Deep Brain Stimulation System
- Where
- 3 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications.
- Trial name
- NCT00282152
- Testing
- B-STN DBS, Optimal drug therapy
- Volunteers
- 37 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease
The purpose of this study is to test the safety and efficacy of using of a portable exoskeleton for walking training in persons with Parkinson's disease that have gait mobility problems and/or postural instability.
- Trial name
- NCT04587193
- Testing
- Robotic-assist gait training device
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University